Premium
Successful treatment with modified CHOP‐rituximab in pediatric AIDS‐related advanced stage Burkitt lymphoma
Author(s) -
Crosswell Howland E.,
Bergsagel Daniel J.,
Yost Robert,
Lew Glen
Publication year - 2008
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21161
Subject(s) - medicine , rituximab , vincristine , prednisone , chop , lymphoma , cyclophosphamide , regimen , oncology , chemotherapy , daunorubicin , immunology
Burkitt lymphoma is the most common AIDS‐related lymphoma (ARL) in childhood. The major issues in adult and pediatric ARL include identifying the optimal chemotherapy regimen and the concurrent treatment of both rituximab and highly active anti‐retroviral therapy (HAART). We present a case of advanced stage Burkitt lymphoma in an 8‐year‐old female with acquired immunodeficiency syndrome (AIDS), who was successfully treated with a 3 month course of modified CHOP‐R (cyclophosphamide, daunorubicin, vincristine, prednisone, and rituximab) and HAART therapy. The combination of rituximab and chemotherapy with HAART therapy may be well‐tolerated and effective in HIV/AIDS patients with Burkitt lymphoma. Pediatr Blood Cancer 2008;50:883–885. © 2007 Wiley‐Liss, Inc.